$4.10
1.44% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US74019P1084
Symbol
DTIL

Precision BioSciences, Inc. Stock price

$4.10
-0.69 14.41% 1M
-0.16 3.76% 6M
-0.06 1.44% YTD
-0.59 12.58% 1Y
-31.60 88.52% 3Y
-259.00 98.44% 5Y
-475.90 99.15% 10Y
-475.90 99.15% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.06 1.44%
ISIN
US74019P1084
Symbol
DTIL
Industry

Key metrics

Basic
Market capitalization
$98.7m
Enterprise Value
$76.2m
Net debt
positive
Cash
$44.9m
Shares outstanding
12.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
141.0 | 10.6
EV/Sales
108.9 | 8.2
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
41.4%
Return on Equity
12.7%
ROCE
-114.0%
ROIC
-
Debt/Equity
1.3
Financials (TTM | estimate)
Revenue
$700.0k | $9.3m
EBITDA
$-88.1m | $-75.5m
EBIT
$-89.5m | $-77.3m
Net Income
$-83.6m | $-75.6m
Free Cash Flow
$-73.7m
Growth (TTM | estimate)
Revenue
-99.1% | -86.4%
EBITDA
-582.1% | -222.0%
EBIT
-452.3% | -195.7%
Net Income
-1,069.8% | -1,154.3%
Free Cash Flow
-52.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-12,625.6% | -809.6%
EBIT
-12,822.6%
Net
-11,977.4% | -810.8%
Free Cash Flow
-10,559.3%
More
EPS
$-7.1
FCF per Share
$-6.1
Short interest
3.4%
Employees
108
Rev per Employee
$640.0k
Show more

Is Precision BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Precision BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Precision BioSciences, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Precision BioSciences, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Precision BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.70 0.70
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
1% 1%
4,941%
- Research and Development Expense 54 54
1% 1%
7,749%
-88 -88
582% 582%
-12,590%
- Depreciation and Amortization 1.38 1.38
58% 58%
197%
EBIT (Operating Income) EBIT -90 -90
452% 452%
-12,786%
Net Profit -84 -84
1,070% 1,070%
-11,943%

In millions USD.

Don't miss a Thing! We will send you all news about Precision BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precision BioSciences, Inc. Stock News

Positive
Seeking Alpha
5 days ago
Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational fl...
Neutral
Business Wire
11 days ago
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision's Board of Directors approved the grant of an inducement award of 8,224 rest...
Positive
Seeking Alpha
about one month ago
Precision BioSciences is advancing a de-risked gene-editing pipeline with promising clinical data and multi-year cash runway. PBGENE-HBV shows compelling early efficacy and safety, positioning DTIL for a potential breakthrough in functional cures for chronic hepatitis B. DTIL maintains a 2/5 conviction rating due to technical weakness, competitive risks, and the need for cleaner bullish signals...
More Precision BioSciences, Inc. News

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Head office United States
CEO Michael Amoroso
Employees 108
Founded 2006
Website precisionbiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today